Other equities research analysts have also recently issued research reports about the company. Credit Suisse Group set a GBX 1,450 ($18.95) target price on GlaxoSmithKline and gave the stock a neutral rating in a research report on Monday, July 16th. JPMorgan Chase & Co. reaffirmed a neutral rating on shares of GlaxoSmithKline in a research report on Tuesday, October 23rd. UBS Group reaffirmed a buy rating and set a GBX 1,700 ($22.21) target price (up previously from GBX 1,600 ($20.91)) on shares of GlaxoSmithKline in a research report on Monday, July 30th. Deutsche Bank reaffirmed a hold rating and set a GBX 1,525 ($19.93) target price on shares of GlaxoSmithKline in a research report on Thursday, September 6th. Finally, Kepler Capital Markets set a GBX 1,440 ($18.82) target price on GlaxoSmithKline and gave the stock a neutral rating in a research report on Monday, July 30th. One analyst has rated the stock with a sell rating, eleven have given a hold rating and nine have assigned a buy rating to the company. The stock has an average rating of Hold and an average target price of GBX 1,521.27 ($19.88).
LON:GSK opened at GBX 1,480 ($19.34) on Wednesday. GlaxoSmithKline has a 52 week low of GBX 1,235.20 ($16.14) and a 52 week high of GBX 1,724.50 ($22.53).
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.
Featured Story: Compound Annual Growth Rate (CAGR)
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.